Ganoderma lucidum transcription factor C3H-2, and application and method thereof in ganoderic acid synthesis
By studying the interaction of the transcription factor C3H-2 of Ganoderma lucidum and SQS and LSS genes, a recombinant vector is constructed to regulate the synthesis of Ganoderma lucidum acid, which solves the problem of low Ganoderma lucidum acid content, and increases the yield of Ganoderma lucidum, providing a new variety of high-quality Ganoderma lucidum Base.
Patent Information
- Application Number
- CN202411326455.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-23
- Publication Date
- 2024-12-03
AI Technical Summary
Ganoderma acid has a low content in Ganoderma lucidum, and the existing extraction methods are inefficient. It is of great significance to analyze its biosynthesis pathway and regulatory mechanism to cultivate high-quality products.
By studying the interaction mechanism of the Ganoderma lucidum transcription factor C3H-2 and SQS and LSS genes, a recombinant vector is constructed to regulate the synthesis of Ganoderma lucidum acid and control the content of Ganoderma lucidum acid.
The synthesis of Ganoderma lucidum acid has been successfully regulated, the production of Ganoderma lucidum acid has been improved, and the foundation for cultivating new high-quality Ganoderma lucidum varieties has been provided.
Smart Images

Figure CN119061025A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of molecular biology and gene engineering, and specifically relates to a ganoderma transcription factor C3H-2 and an application and method in the synthesis of ganoderic acid. Background Art
[0002] Ganoderma Lucidum is a traditional large fungus with medicinal and edible properties, which has the effects of replenishing qi and calming the mind, relieving cough and relieving asthma. Ganoderma contains a variety of bioactive ingredients, with extremely high nutritional and health value and economic development prospects. Triterpenes are the main bioactive secondary metabolites in Ganoderma, among which Ganoderma triterpenoid acids, referred to as Ganoderic acids (GAs), are the core components of Ganoderma's medicinal effects. Studies have shown that Ganoderic acids play an important role in tumor treatment, anti-oxidation, inhibition of cholesterol synthesis, inhibition of angiotensin converting enzyme activity, inhibition of histamine release, and anti-HIV. However, the main way to obtain Ganoderic acid is to extract it from Ganoderma fruiting bodies and spores, and the content of Ganoderic acid in Ganoderma is relatively low. Therefore, analyzing the biosynthetic pathway of Ganoderic acid and its regulatory mechanism is of great significance for cultivating Ganoderma varieties with high Ganoderic acid production.
[0003] Ganoderic acid is synthesized through the mevalonate pathway (MVA) with acetyl-CoA as the precursor. In the MVA pathway, there are two important branches for the synthesis of ganoderic acid, one branch is from farnesyl pyrophosphate to geranyl pyrophosphate, and the other branch is from farnesyl pyrophosphate to lanosterol. The key genes that have been cloned and reported in these two branches are FPS, MVD, AACT, LS, HMGR, HMGS, IDI, SQS and OSC genes, which directly regulate the synthesis of ganoderic acid and are the key to the synthesis and accumulation of ganoderic acid. Among them, squalene synthase (SQS) is the first key enzyme that catalyzes the transition of the MVA pathway to triterpene biosynthesis, and is also a key enzyme involved in the anabolism of ganoderic acid. Squalene synthase (SQS) can catalyze the carbon flow in the isoprene pathway to triterpene biosynthesis. The activity of SQS is related to the production of triterpene compounds such as squalene, and is a key enzyme in the synthesis of triterpene compounds such as squalene. In recent years, studies have cloned and constructed vectors of SQS genes in different plants such as ginseng, rice, and Paris polyphylla, exploring the mechanism of triterpenoid synthesis in plants at the molecular level and exploring the optimal conditions for gene expression through gene transformation; lanosterol synthase (LSS) is a key enzyme in the cholesterol synthesis pathway, catalyzing the conversion of (S)-2,3-epoxysqualene into lanosterol.
[0004] Based on the above background, this patent studies the interaction mechanism between SQS gene and LSS gene of Ganoderma lucidum and transcription factor C3H-2, provides a certain basis for the regulatory mechanism of ganoderic acid, and is also of great significance for the cultivation of high-quality new varieties of Ganoderma lucidum. Summary of the invention
[0005] In order to solve the above problems, the present invention provides a key transcription factor C3H-2 which catalyzes the synthesis of lanosterol into ganoderic acid.
[0006] In one aspect, the present invention provides a Ganoderma lucidum transcription factor C3H-2, the nucleotide sequence of the Ganoderma lucidum transcription factor C3H-2 is shown in SEQ ID NO.1, or a sequence having a sequence similarity of more than 80% to SEQ ID NO.1.
[0007] Specifically, the nucleotide sequence of the Ganoderma lucidum transcription factor C3H-2 is as shown in SEQ ID NO.1, or a sequence having a sequence similarity of more than 85% to SEQ ID NO.1.
[0008] More specifically, the nucleotide sequence of the Ganoderma lucidum transcription factor C3H-2 is as shown in SEQ ID NO.1, or a sequence having a sequence similarity of more than 90% with SEQ ID NO.1.
[0009] Preferably, the nucleotide sequence of the Ganoderma lucidum transcription factor C3H-2 is as shown in SEQ ID NO.1, or a sequence having a sequence similarity of more than 95% with SEQ ID NO.1.
[0010] Further preferably, the nucleotide sequence of the Ganoderma lucidum transcription factor C3H-2 is as shown in SEQ ID NO.1, or a sequence having a sequence similarity of more than 98% with SEQ ID NO.1.
[0011] In yet another aspect, the present invention provides a recombinant vector comprising the aforementioned nucleotide sequence.
[0012] Specifically, the types of the recombinant vector include but are not limited to: plasmid, phage or virus.
[0013] More specifically, the type of the recombinant vector can be a plasmid.
[0014] Preferably, the plasmid may be pGADT7-AD or pGreenII 62-SK.
[0015] Further preferably, when the plasmid is pGADT7-AD, the primers for amplifying the Ganoderma lucidum transcription factor C3H-2 are shown as SEQID NO.5-6; when the plasmid is pGreenII 62-SK, the primers for amplifying the Ganoderma lucidum transcription factor C3H-2 are shown as SEQID NO.7-8.
[0016] In another aspect, the present invention provides a cell containing the aforementioned Ganoderma lucidum transcription factor C3H-2 or the recombinant vector.
[0017] Specifically, the cell is a genetically engineered bacterium.
[0018] More specifically, the genetically engineered bacteria include but are not limited to: Escherichia coli, yeast, Agrobacterium, actinomycetes or filamentous fungi.
[0019] Preferably, further preferably, the genetically engineered bacteria may be yeast or Agrobacterium.
[0020] In yet another aspect, the present invention provides the use of the aforementioned Ganoderma lucidum transcription factor C3H-2 in activating the expression of Ganoderma lucidum SQS gene and LSS gene.
[0021] In yet another aspect, the present invention provides a method for synthesizing ganoderic acid, wherein the method performs biosynthesis through the aforementioned ganoderic transcription factor C3H-2 or the aforementioned recombinant vector or the aforementioned cell.
[0022] In another aspect, the present invention provides the use of the aforementioned Ganoderma transcription factor C3H-2 or recombinant vector or cell or method in the synthesis of ganoderic acid.
[0023] The technical effects achieved by the present invention are:
[0024] (1) The Ganoderma lucidum transcription factor C3H-2 positively regulates the expression of SQS and LSS by binding to the promoters of the SQS and LSS genes.
[0025] (2) The Ganoderma lucidum transcription factor C3H-2 can regulate the key enzyme genes involved in the synthesis and metabolism of ganoderic acid, thereby achieving the regulation of the ganoderic acid content in Ganoderma lucidum. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 This is a heat map of C3H-2 gene expression.
[0027] Figure 2 This is a map of the recombinant vector pGADT7-C3H-2.
[0028] Figure 3 This is the map of the recombinant vector pGreenII 62SK-C3H-2.
[0029] Figure 4Analyze the results for yeast one-hybrid assay.
[0030] Figure 5 These are the analysis results of the dual luciferase reporter experiment, where A is the analysis result of the dual luciferase reporter experiment; and B is the fluorescence imaging result. DETAILED DESCRIPTION
[0031] The present invention will be further described in detail below in conjunction with specific examples. The following examples are not intended to limit the present invention, but are only intended to illustrate the present invention. The experimental methods used in the following examples are generally conventional, unless otherwise specified, and the materials, reagents, etc. used in the following examples are commercially available, unless otherwise specified.
[0032] The C3H-2, SQS and LSS in the present invention are all derived from Ganoderma lucidum.
[0033] Example 1 Yeast one-hybrid assay
[0034] To determine whether C3H-2 can directly regulate SQS and LSS genes, we first performed a yeast one-hybrid assay:
[0035] 1.1 Construction of recombinant vector
[0036] Using the gDNA of the Ganoderma lucidum variety Xianzhi No. 1 as a template, the promoter region of 2000 bp before the start codon ATG of the SQS gene was cloned (the nucleotide sequence is shown in SEQ ID NO.3), and constructed into the pAbAi vector (manufacturer: Shanghai Zeye Biological Co., Ltd.; product number: ZY8159; insertion site: HindIII, XmaI), and the recombinant vector pAbAi-SQS was obtained. The primer sequences for amplifying the promoter region of the SQS gene are shown in SEQ ID NO.9-10: SEQ ID NO.3:
[0037]
[0038] SEQ ID NO.9(F): 5ˊ-TAGGGTCTGCTCGATTTTCG-3ˊ;
[0039] SEQ ID NO. 10(R): 5ˊ-TATGACGAAAGAGTTGGTAG-3ˊ.
[0040] Using the gDNA of the Ganoderma lucidum variety Xianzhi No. 1 as a template, the promoter region of 2000bp before the start codon ATG of the LSS gene was cloned, and 788bp to 1568bp upstream of LSS was selected as the promoter region to obtain the sequence of LSS. The sequence of LSS is shown in SEQ ID NO.4, and the primer sequences for amplifying the LSS sequence are shown in SEQ ID NO.11-12. It was constructed into a pAbAi vector (manufacturer: Shanghai Zeye Biological Co., Ltd.; product number: ZY8159; insertion site: HindIII, XmaI) to obtain the recombinant vector pAbAi-LSS.
[0041] SEQ ID NO.4
[0042] ATTTCCTCCTTCCTCGTTCGCAAACCTTGAGTTCCTTGGATTTATCGTCGATGGGACCAACTGGCTGGGTGTCGCGGACTTCCTGCGACCCCTCCCAGCCCACCTTGATACGCTTGTCATCTTTGTTCGGGATAAAGATGAGGTGGTGGGCAAAGACCTGCTGATGAAAGAGGATGGCGAAGTCAAAGCGATGAGGACCAACGGCTTGGAGCACCTTGATACAGTGCTGTCCCTCGACAGCTTCAAGGACTTACGTTGCTTGCAGTTCCGAGTTGTGCGTAGCGGAGACACGCTGGACTCTATCAGAGGACTACGCTTCATGCCATTCAGCGGAAACTACCCACATTGCATAGTCGTGCTAGCTTGAACATTCAGCTACACCTCTAGTATGACCACCAACTCTCCTATCTCCCGGAGCTGAGAGCATTGGCCAGGTTGAAGAATCTGCTGCTCGATCTTGCGGTACGAGAGTGCAATACCCTGCCTTATTTTTTTTTTCAAACGAGTCTAACTTCTCCTTCGTCTTAGGGATCTCGCGAGTTTCAACTGGACCTGCGAGCGCACTCACGCTCGTAGGTATCAGTGTATGCAAAACGGCGGAGCCGCGATATTCATCGAAGTGGACTACCCCTCCTTCTGCCATCCCGAACCACCTCAGTTGACAGAGACCGCCCTGCGTAATGGGGACTCGGAGATCACGATGGCGACGATTGAACGCATGGACGAATTCGCAGTAACAGTACTTGTATTCATATTTATTTCGCTGAGATTGGAGACAAT;
[0043] SEQ ID NO.11(F):5ˊ-ATTTCCTCCTTCCTC-3ˊ;
[0044] SEQ ID NO.12(R):5ˊ-TGTCTGAACGATGCG-3ˊ。
[0045] Using the cDNA of the Ganoderma lucidum variety Xianzhi No. 1 as a template, the full-length coding region of the C3H-2 gene was cloned (the CDS sequence of C3H-2 is shown in SEQ ID NO.1, and the amino acid sequence is shown in SEQ ID NO.2), and the homologous recombination primer sequences used to amplify the C3H-2 CDS region are shown in SEQ ID NO.5 and SEQ ID NO.6, respectively. The construct was constructed into the pGADT7-AD vector to obtain the recombinant vector pGADT7-C3H-2.
[0046] SEQ ID NO.1:
[0047]
[0048] SEQ ID NO.2:
[0049] MADTENLTVPFFKKKGRGRPTTSRKRSASPPATAMTAPVASSSKSEVVLPSRKAAANLLSAGTKRTASQRQDDDDQEDTREGPDVKWTAAGSHVNAALEILQGDEAAELLAKRRKFEKKDEEEEEVPDDGLYRGQKAYTSHIRKNKEVPKAMRVGPQRSNNSTIRT VTIVDYQPDVCKDYKETGYCGYGDTCKFLHDRGTYLQGWQLDKLAADPKKQAGEDVSDTDSDDEDIPFACVVCRKPYTDPVVTRCEHYFCSACAIKRFAKTPKCAACGAPTGGIFNRADKVIAKLKKKQEDRDREGEDGEGEGAAGGVQIEGLGHANGSEDEDEE;
[0050] SEQ ID NO.5(F):
[0051] CCATGGAGGCCAGTGAATTCATGGCTGATACTGAGAACGTC;
[0052] SEQ ID NO.6(R):
[0053] CGATTCATCTGCAGCTCGAGGTCTTCGTCCTCGTCCTC.
[0054] 1.2 Transfection of cells
[0055] The recombinant vectors (pAbAi-SQS and pAbAi-LSS) constructed on pAbAi were co-transformed with the pGADT7-AD empty vector into the yeast competent cell Y2H (manufacturer: Shanghai Jingkang Bioengineering Co., Ltd.; catalog number: JK-G8044) as the control group, and co-transformed with the pGADT7-AD recombinant vector as the experimental group, and applied to the (SD / -ura / -leu) defective medium and cultured at 30°C for 3-4 days. More than 10 positive clones were selected and cultured in a shaking incubator at 30°C with (SD / -ura / -leu) liquid culture medium until the OD 600 >1.5, centrifuge at 1000rpm for 2min, discard the supernatant, and resuspend with sterile water to OD 600≈0.2, and cultured at 30°C for 2-3 days on SD-Leu / -Ura solid medium containing AbA (Aureobasidin A) at the original multiple, 1 / 10, 1 / 100, and 1 / 1000. The results showed that by adding 100 ng / mL of AbA to inhibit the self-activation of the promoter on the (SD / -ura / -leu) defective medium, it was found that the growth ability of the combination of C3H-2 co-transformed with SQS and LSS was significantly better than that of the control ( Figure 4 ), indicating that C3H-2 can directly bind to the SQS and LSS promoters in yeast cells.
[0056] Example 2 Dual luciferase reporter assay
[0057] The dual luciferase system was used to analyze the transcriptional activity of C3H-2 protein on the SQS gene in tobacco to verify the transcriptional activity. The pGreenII-62sk-C3H-2, pGreenII-0800-SQS (pGreenII-0800 manufacturer: Shanghai Zeye Biotechnology Co., Ltd.; product number: ZY6124; insertion site: HindIII, XmaI) and pGreenII-0800-LSS promoter recombinant vectors were constructed (the homologous recombination primer sequences used to amplify the C3H-2 CDS region are shown in SEQ ID NO.7 and SEQ ID NO.8, respectively), and transformed into GV3101-pSoup-P19 Agrobacterium tumefaciens competent cells (manufacturer: Shanghai Weidi Biotechnology Co., Ltd.; product number: AC1003M). Before use, Agrobacterium (pGreenII-62sk-C3H-2, pGreenII-0800-SQS and pGreenII-0800-LSS promoters and bacterial solution) stored at -80℃ was streaked on LB+50 μg / mL kanamycin (kanamycin, Kan)+25 μg / mL rifampicin (rif) solid medium, and then a single clone was picked and inoculated into 0.6 mL and then inoculated into 5 mL and 20 mL of the above liquid medium in a ratio of 1:100 overnight until the stable period OD600 > 2.0, and the bacterial precipitate was collected after centrifugation at 5000 rpm for 10 minutes at room temperature, and the bacterial solution was resuspended and mixed with 1×MMA solution until the final transcription factor and promoter OD600 = 0.5, and placed at room temperature in the dark for 3 hours before injection into Nicotiana benthamiana. Select 4-5 weeks old healthy Nicotiana benthamiana and keep it in the dark for 24 hours. After injection, place in the dark for 1-2 days, then light cycle 14 / 10 h for 3-4 days, then select 0.5cm2 injection area and add 500 μL of Glo lysis solution (manufacturer: Beijing Zhaosheng Lab Trading Co., Ltd.; item number: 0000566337) for grinding. After full lysis, centrifuge at 12000rpm 4 ℃ for 3 min, take 50μL supernatant + 50μL luciferin reaction substrate and react at room temperature for 10 minutes, use a microplate reader to measure luciferase fluorescence A, then add 50μL of stop solution to react for 10 minutes and then measure its Renilla fluorescence B, and calculate whether there is an interaction between the transcription factor and the promoter by the A / B ratio. The results of the dual luciferase reporter experiment show ( Figure 5 ), C3H-2 can activate the expression of promoters SQS and LSS.
[0058] SEQ ID NO.7(F):
[0059] CTAGAACTAGTGGATCCATGGCTGATACTGAGAACGTC;
[0060] SEQ ID NO.8(R):
[0061] CGGTATCGATAAGCTTGTCTTCGTCCTCGTCCTC.
[0062] It should be understood that the various forms of processes shown above can be used to reorder, add or delete steps. For example, the steps described in the disclosure of the present invention can be performed in parallel, sequentially or in different orders, as long as the desired results of the technical solution disclosed in the present invention can be achieved, and this document does not limit this.
[0063] The above specific implementations do not constitute a limitation on the protection scope of the present invention. It should be understood by those skilled in the art that various modifications, combinations, sub-combinations and substitutions can be made according to design requirements and other factors. Any modification, equivalent substitution and improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims
1. A Ganoderma lucidum transcription factor C3H-2, It is characterized in that The nucleotide sequence of the Ganoderma lucidum transcription factor C3H-2 is shown in SEQ ID NO.1, or a sequence having a sequence similarity of more than 80% with SEQ ID NO.
1.
2. A recombinant vector, It is characterized in that The recombinant vector comprises the nucleotide sequence according to claim 1.
3. The recombinant vector according to claim 2, It is characterized in that The type of the recombinant vector is plasmid, phage or virus, preferably plasmid.
4. The recombinant vector according to claim 3, It is characterized in that The plasmid is pGADT7-AD or pGreenII62-SK.
5. The recombinant vector according to any one of claims 3 to 4, It is characterized in that When the plasmid is pGADT7-AD, the primers for amplifying the Ganoderma lucidum transcription factor C3H-2 are shown in SEQ ID NOs.5-6; when the plasmid is pGreenII 62-SK, the primers for amplifying the Ganoderma lucidum transcription factor C3H-2 are shown in SEQ ID NOs.7-8.
6. A cell comprising the Ganoderma lucidum transcription factor C3H-2 according to claim 1 or the recombinant vector according to any one of claims 2 to 5.
7. The cell according to claim 6, It is characterized in that The cell is a genetically engineered bacterium; preferably Escherichia coli, yeast, Agrobacterium, actinomycetes or filamentous fungi; more preferably yeast or Agrobacterium.
8. Use of the Ganoderma lucidum transcription factor C3H-2 according to claim 1 in activating the expression of Ganoderma lucidum SQS gene and LSS gene.
9. A method for synthesizing ganoderic acid, It is characterized in that The method is carried out biosynthesis by using the Ganoderma transcription factor C3H-2 described in claim 1 or the recombinant vector described in any one of claims 2-5 or the cell described in any one of claims 6-7.
10. Use of the Ganoderma transcription factor C3H-2 according to claim 1, the recombinant vector according to any one of claims 2 to 5, the cell according to any one of claims 6 to 7, or the method according to claim 9 in synthesizing ganoderic acid.
Citation Information
Cited By
Ganoderma lucidum transcription factor Zn-8 and derivative thereof, and application and method of ganoderma lucidum transcription factor Zn-8 in synthesis of ganoderic acid
CN120118922A
Application and method of ganoderma lucidum transcription factor yabby1 in regulating and controlling transcriptional activity of ganoderic acid synthetic gene SQS
CN120624472A
Application and method of bHLH family gene in ganoderma lucidum in synthesis of ganoderic acid
CN120624473A
